<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04964752</url>
  </required_header>
  <id_info>
    <org_study_id>PL-CGM-202006</org_study_id>
    <nct_id>NCT04964752</nct_id>
  </id_info>
  <brief_title>A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes</brief_title>
  <official_title>Effectiveness and Safety Study of the Continuous Glucose Monitoring System for Home Use (Including In-clinic Sessions) in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Powder (Guangzhou) Pharmaceuticals Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Powder Pharmaceuticals (HK) Co., Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects in the upper arm group will have a sensor of the CGM System inserted on each arm&#xD;
      (left and right upper arm). Subjects in the abdomen group will have 2 sensors inserted, one&#xD;
      on each side of the abdomen (left and right abdomen) The sensors will be placed for 29 days.&#xD;
      After sensor insertion, the CGM system should be calibrated with capillary blood glucose&#xD;
      readings from a self-monitoring blood glucose meter。&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>%20/20 agreement between the test device readings and the EKF readings: %20/20 = A + B</measure>
    <time_frame>up to 29 days</time_frame>
    <description>A = the proportion of the CGM system values that were within ±20% of paired EKF values &gt;4.4mmol/L (&gt;80 mg/dL) B = the proportion of the CGM system values that were within ±1.1mmol/L (20mg/dL) of paired EKF values ≤4.4mmol/L (≤80mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of readings in Region A + Region B of Clarke Error Grid</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Analyze the proportion of readings in each region (Region A, B, C D and E). Readings in Region A are clinically accurate, while readings in Region B are of clinically acceptable accuracy. Readings in C, D and E are inaccurate to various degrees.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of readings in Region A + Region B of Consensus Error Grid</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Analyze the proportion of readings in Region A and Region B.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the percentage of MARD (Mean Absolute Relative Difference)</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Analyze the proportion of readings in MARD &lt;18% (95%CI&lt;20%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alarm success rate1</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Hypoglycemia alarm success rate and failure rate (sensitivity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alarm success rate2</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Hypoglycemia detection rate and missed detection rate (specificity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alarm success rate 3</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Hyperglycemia alarm success rate and failure rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alarm success rate 4</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Hyperglycemia detection rate and missed detection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensor Stability</measure>
    <time_frame>up to 29 days</time_frame>
    <description>Compare the accuracy of the sensor between Day 2(22h~48h after insertion), Day 15±1day, Day 29±1day to evaluate sensor.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>the upper arm group on Day 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The upper arm group to perform Visit 3 venous blood glucose measurement on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the upper arm group on Day 15±1 day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The upper arm group to perform Visit 3 venous blood glucose measurement on Day 15±1 day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the upper arm group on Day 29±1 day</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The upper arm group to perform Visit 3 venous blood glucose measurement on Day 29±1 day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the abdomen group on Day 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The abdomen group to perform Visit 3 venous blood glucose measurement on Day 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the abdomen group on Day 15±1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The abdomen group to perform Visit 3 venous blood glucose measurement on Day 15±1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the abdomen group on Day 29±1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The abdomen group to perform Visit 3 venous blood glucose measurement on Day 29±1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous glucose-monitoring</intervention_name>
    <description>Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.</description>
    <arm_group_label>the abdomen group on Day 15±1</arm_group_label>
    <arm_group_label>the abdomen group on Day 2</arm_group_label>
    <arm_group_label>the abdomen group on Day 29±1</arm_group_label>
    <arm_group_label>the upper arm group on Day 15±1 day</arm_group_label>
    <arm_group_label>the upper arm group on Day 2</arm_group_label>
    <arm_group_label>the upper arm group on Day 29±1 day</arm_group_label>
    <other_name>CGM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Type 1 or 2 diabetes mellitus&#xD;
&#xD;
          2. Male or female age ≥ 18 years old and ≤ 70 years old&#xD;
&#xD;
          3. Willingness to adopt measures to prevent water coming into contact with the device&#xD;
             sensor (e.g. abstain from swimming, sauna, avoid hitting the sensor with direct jets&#xD;
             of water)&#xD;
&#xD;
          4. Ability to communicate with the investigators, able to operate medical device after&#xD;
             training and comply with the testing procedures outlined in this protocol (including,&#xD;
             but not limited to, willing to wear the continuous glucose monitor and testing&#xD;
             capillary blood glucose)&#xD;
&#xD;
          5. Subjects who show understanding of the study procedures and willing to sign a written&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalization due to diabetic ketoacidosis or severe hypoglycemia, within 3 months&#xD;
             prior to screening&#xD;
&#xD;
          2. HbA1c &gt;13% or urine ketone 3+&#xD;
&#xD;
          3. Use of pacemaker&#xD;
&#xD;
          4. Body Mass Index (BMI) ≤18.0kg/m2&#xD;
&#xD;
          5. Extensive skin changes/diseases that preclude wearing the required number of devices&#xD;
             on normal skin at the proposed application sites, i.e. upper arm or abdomen (e.g.,&#xD;
             extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive&#xD;
             scarring, extensive tattoos, dermatitis herpetiformis)&#xD;
&#xD;
          6. Any psychiatric disease such as depression or anxiety&#xD;
&#xD;
          7. Any severe hepatic, renal, cardiac, cerebral, respiratory or neurological diseases&#xD;
             (e.g. serum ALT, AST, Creatinine level ≥3 times the upper limit of normal)&#xD;
&#xD;
          8. Has a MRI scan, CT scan or other procedure requiring the subject be under strong&#xD;
             magnetic or electromagnetic environment, scheduled during the proposed study&#xD;
             participation&#xD;
&#xD;
          9. Blood loss &gt;400ml in the past 3 months (including blood donation)&#xD;
&#xD;
         10. Have a known allergy to medical-grade adhesives, or known hypersensitivity to any of&#xD;
             the products used in the study&#xD;
&#xD;
         11. Difficulty in sampling venous blood or cannot tolerate venipuncture&#xD;
&#xD;
         12. Participated in other investigational studies in the past 3 months&#xD;
&#xD;
         13. Currently pregnant or lactating women, or positive pregnancy test&#xD;
&#xD;
         14. Any condition that, in the opinion of the investigator, renders the subject not&#xD;
             suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elaine Chow, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Prince of Wales Hospital, the Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elaine Chow, Prof.</last_name>
    <phone>(852) 3505 1642</phone>
    <email>e.chow@cuhk.edu.hk</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 11, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

